Mocetinostat (MGCD0103)

For research use only.

Catalog No.S1122 Synonyms: MG0103

80 publications

Mocetinostat (MGCD0103) Chemical Structure

CAS No. 726169-73-9

Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) EUR 186 In stock
EUR 167 In stock
EUR 265 In stock
EUR 461 In stock
EUR 756 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Mocetinostat (MGCD0103) has been cited by 80 publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Mocetinostat (MGCD0103, MG0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
HDAC11 [1]
(Cell-free assay)
HDAC3 [1]
(Cell-free assay)
0.15 μM 0.29 μM 0.59 μM 1.66 μM
In vitro

MGCD0103 inhibits only a subset of the nine human recombinant HDACs, including HDAC1, HDAC2, HDAC3, and HDAC11 at nanomolar or low micromolar concentrations, in a dose-dependent manner. MGCD0103 reveals most potent inhibitory activity against human HDAC1 and HDAC2 enzymes in vitro, and it does not inhibit class II HDACs. The exocyclic amino group in MGCD0103 is necessary for enzyme inhibitory activity because HDAC-inhibitory activity against HDAC1 and HDAC2 is completely abolished with the desamino analogue. The inhibitory activity of MGCD0103 reaches the maximum plateau at 6 μM, and the maximal inhibitable enzyme pool affected by MGCD0103 is 75% of the total enzyme activity in HCT116 cells whereas NVP-LAQ824 inhibits almost 100% of that in these cells. In A549 cells, MGCD0103 also exhibits dose-dependent inhibition of HDAC activity in whole cells. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MDA-MB-231 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn1OFghcA>? NUTqd2t7UUN3ME2zMlA1KM7:TR?= NFP4b24zPjN5OECzPC=>
BT549 NW\kTVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M132SFQ5KGh? Ml;ITWM2OD12LkO4JO69VQ>? NHjDWIozPjN5OECzPC=>
MCF7 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rrTlQ5KGh? NWLIN3R3UUN3ME2wMlY4KM7:TR?= MnnMNlY{PzhyM{i=
T47D NF7DTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYVFQ5KGh? MWHJR|UxRTFwMUeg{txO M3e4OlI3Ozd6MEO4
MOLP8 Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHYOmJCPDhiaB?= NHTVc4hKSzVyPUCuOuKyKDBwMEVOwG0> NWflS4VMOjZyOUG1NVg>
Panc1 MYXGeY5kfGmxbjDBd5NigQ>? MVSwMlUwOS9{LkWg{txO NW[wemVTPDhiaB?= NILYdYZFVVOR NI\td492eHKnZ4XsZZRmeyCvaWKtNlA{ NHvkSVUzPTh5Mkm0NS=>
Panc1 NILSVmFHfW6ldHnvckBCe3OjeR?= M4PuVlAvPS9zL{KuOUDPxE1? NF\EbHI1QCCq NYr0O2JXTE2VTx?= NWnjV3lTemWmdXPld{BmgHC{ZYPzbY9vKG:oIGrFRlEhd25iYn;0bEBuWk6DIHHu[EBxem:2ZXnuJIxmfmWuwrC= MWCyOVg4Ojl2MR?=
Panc1 MYrBdI9xfG:|aYOgRZN{[Xl? MUWxxsDPxE1? NVf6em9HPzMEoHi= MUjEUXNQ NYe5XWlwe2Wwc3n0bZpmeyCSYX7jNUBk\WyuczDmc5Ih\2WvY3n0ZYJqdmVvaX7keYNm\CCjcH;weI9{cXN? NHzHd2gzPTh5Mkm0NS=>
Panc1 MoHTR4VtdCCYaXHibYxqfHliQYPzZZk> NGTINlMyyqEQvF2= MonIO|LDqGh? MX7EUXNQ M1;QUYVvcGGwY3XzJIdmdWOrdHHibY5mNWmwZIXj[ZMh[2WubDD2bYFjcWyrdImg[IVkemWjc3W= NHfJfFgzPTh5Mkm0NS=>
MMCs NIq5W3ZHfW6ldHnvckBCe3OjeR?= NXfZUlhKOSEQvH2= M{DQdlAuPDhiaB?= M4LSb4lv[3KnYYPld{BPWFKDIIDyc5RmcW5iZYjwdoV{e2mxbtMgNk446oDVMz61JIZwdGR? M4LlS|I1PDVzM{e4
MMCs M2\kUWZ2dmO2aX;uJGF{e2G7 M3TlR|AvPS9zIN88US=> NHWz[mwzPCCq M3;LfJNpd3e|IES1MYZwdGRic4TpcZVt[XSrb36gbY4h[0ePUDDs[ZZmdHN? NX65T|U6OjR2NUGzO|g>
MMCs MkL3SpVv[3Srb36gRZN{[Xl? MYixxsDPxE1? M3SydFI1KGh? MVjpcoNz\WG|ZYOgTGFVKGGldHn2bZR6 MUiyOFQ2OTN5OB?=
MMCs NHvMPI5HfW6ldHnvckBCe3OjeR?= NHvjTo8yyqEQvF2= MlfONlQhcA>? NIrROGtifWevZX70d{BodG:kYXygZYNmfHmuYYTpc44hdGW4ZXzzJI9nKGirc4TvcoUhUDNvS{mvNVQhMEh|LVu5M|E1[WNrIHHu[EBJPC2NMUKgLGg1NUtzMnHjLS=> NGHqcmQzPDR3MUO3PC=>
MMCs M1W0T2Z2dmO2aX;uJGF{e2G7 NWLHRYJFOcLizszN MX[2MVI1KGh? MXXkc5NmNWSncHXu[IVvfGy7IHnubIljcXS|IITo[UB1emmvZYTofYxifGmxbjDs[ZZmdCCxZjDIN{1MQSBqSEOtT|lu\TNr NUjaZlNSOjR2NUGzO|g>
BxPC-3 M1fiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofBSWM2OD1zLkGg{txO MXKyNVM4PTZ5OR?=
AsPC-1 M1\FbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XjXWVEPTB;Mz65JO69VQ>? MVWyNVM4PTZ5OR?=
MiaPaca-2 NVKxb5Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XRUmVEPTB;MD62JO69VQ>? NWPaXYhwOjF|N{W2O|k>
Panc-1 NHjae2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFX3TWdGSzVyPUGuPEDPxE1? MlfiNlE{PzV4N{m=
PAXF 546L† MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OzemVEPTB;MT61JO69VQ>? NF36VmMzOTN5NU[3PS=>
PAXF 1657L† NHPoNJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXHellFTUN3ME2wMlMh|ryP M2GycVIyOzd3Nke5
HCT15 NXezNG5DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L3U2lEPTB;MD63JO69VQ>? NUPaS4hsOjF|MUe0OVU>
HT-29 NGnB[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXjbnNMUUN3ME2wMlch|ryP Ml;jNlE{OTd2NUW=
SW48 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTBwODFOwG0> MVqyNVMyPzR3NR?=
SW620 NILaNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLJclNKSzVyPUGg{txO NIP3O3czOTNzN{S1OS=>
HMEC NH3Z[oVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkn0TWM2OD1zOTFOwG0> M{jP[VIyOzF5NEW1
ANBL6  NGnzW3lHfW6ldHnvckBCe3OjeR?= MVixxsDPxE1? MWWyOEBp NFGyd3ZmdmijbnPld{A2NUGFLXnu[JVk\WRiTVHHSU1COyCpZX7lJIV5eHKnc4Ppc44> NV7sfolCOjFzN{G4NlE>
LP1 MoWzSpVv[3Srb36gRZN{[Xl? MmTjNeKh|ryP NH\rNo8zPCCq MkHL[Y5p[W6lZYOgOU1CSy2rbnT1Z4VlKE2DR1WtRVMh\2WwZTDlfJBz\XO|aX;u M4XHc|IyOTdzOEKx
HD-LM2 NYDBOVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\GPVczyqCq M33MVGROW09? M2n2OmlEPTB;MT64PEDPxE1? MWOyNFg5ODFyNx?=
L428 M{TlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2L0S|czyqCq NIfVXlVFVVOR MXLJR|UxRTFwOU[g{txO MVWyNFg5ODFyNx?=
KM-H2 M33YcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\GO|czyqCq MWnEUXNQ NUTxeHAyUUN3ME2yMlg3KM7:TR?= M2ns[VIxQDhyMUC3
HD-LM2 MWrGeY5kfGmxbjDBd5NigQ>? NUPsS24yOC5zLUKg{txO MnTkNlQhcMLi MmDuSG1UVw>? NWXsTFdne2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=> MWiyNFg5ODFyNx?=
L428 MVjGeY5kfGmxbjDBd5NigQ>? NE\PO5kxNjFvMjFOwG0> MlnXNlQhcMLi MUjEUXNQ NX35c5A6e2ixd4OgZYNmfHmuYYTpc44hd2ZiaHnzeI9v\SB|IHHu[EB2eHKnZ4XsZZRqd25ib3[geIhmKGOnbHygZ5lkdGVicnXneYxifG:{eTDwdo91\WmwIICyNS=> Ml3tNlA5QDBzMEe=
KM-H2 MVPGeY5kfGmxbjDBd5NigQ>? M2XaTlAvOS1{IN88US=> NVjzUVNyOjRiaNMg NX7RXVBvTE2VTx?= M2fKZpNpd3e|IHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhOyCjbnSgeZBz\We3bHH0bY9vKG:oIITo[UBk\WyuIHP5Z4xmKHKnZ4XsZZRwenlicILveIVqdiCyMkG= NYfp[5Y6OjB6OECxNFc>
HD-LM2 NWXrN2dySXCxcITvd4l{KEG|c3H5 NX3NOoJNOC5zL{CuOU8yKM7:TR?= NU\IOZJGPDhiaB?= M4fvS2ROW09? MnjKbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= MmPGNlA5QDBzMEe=
L428 NHzhNY1CeG:ydH;zbZMhSXO|YYm= M1nPOFAvOS9yLkWvNUDPxE1? MnWxOFghcA>? MVfEUXNQ MYPpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MVGyNFg5ODFyNx?=
KM-H2 NUnSTY1FSXCxcITvd4l{KEG|c3H5 MUmwMlEwOC53L{Gg{txO MUe0PEBp M3HkfmROW09? MnjJbY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= NVTtZplROjB6OECxNFc>
HD-LM2 MmX4SpVv[3Srb36gRZN{[Xl? NF7KVVkyyqEQvF2= NH:0TpUzPC92ODDo NWS3fnJNTE2VTx?= NY\4bG5X\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>? MoLINlA5QDBzMEe=
L428 MkThSpVv[3Srb36gRZN{[Xl? NEDkV|QyyqEQvF2= MoG2NlQwPDhiaB?= NYDTN4g6TE2VTx?= NXXsW5lu\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>? Moe1NlA5QDBzMEe=
KM-H2 MYLGeY5kfGmxbjDBd5NigQ>? MnmwNeKh|ryP MknJNlQwPDhiaB?= M33nWWROW09? NWX6dIc6\G:5boLl[5Vt[XSnczDYTWFRNCCjY4TpeoF1\WRiY3HzdIF{\XNiOTDhcoQhOw>? MVmyNFg5ODFyNx?=
HD-LM2 Mmr0SpVv[3Srb36gRZN{[Xl? NWi3PGtqOC53L{Gg{txO NFLTZXEzPC92ODDo MmfiSG1UVw>? NFLqS3J2eHKnZ4XsZZRmeyCWTl[t{tEh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NXPrc3dMOjB6OECxNFc>
L428 M3\kdWZ2dmO2aX;uJGF{e2G7 NWTESFJuOC53L{Gg{txO MYWyOE81QCCq NX24UZV{TE2VTx?= M4PYcZVxemWpdXzheIV{KFSQRj5OtUBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 NH7hU24zODh6MEGwOy=>
KM-H2 MWHGeY5kfGmxbjDBd5NigQ>? MV2wMlUwOSEQvF2= MUOyOE81QCCq NW\s[md4TE2VTx?= MWL1dJJm\3WuYYTld{BVVkZvzsGg[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NHjlS3ozODh6MEGwOy=>
HD-LM2 M{\mfWZ2dmO2aX;uJGF{e2G7 MnTmNeKh|ryP M37vT|AvOjVvNEigbC=> MU\EUXNQ M4TheoFkfGm4YYTld{BPTi2tQh?= MkjLNlA5QDBzMEe=
L428 NYTJS3hxTnWwY4Tpc44hSXO|YYm= NFT2XocyyqEQvF2= MlTGNE4zPS12ODDo NYS5OVd7TE2VTx?= Ml7mZYN1cX[jdHXzJG5HNWuE M4KyT|IxQDhyMUC3
KM-H2 MYrGeY5kfGmxbjDBd5NigQ>? M2LpXFHDqM7:TR?= NXzmeXByOC5{NT20PEBp NXLMNmFTTE2VTx?= Mkn4ZYN1cX[jdHXzJG5HNWuE NHS4bIMzODh6MEGwOy=>
H526 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP2[YxRUUN3ME20PFAhdk1? NX\LN|l6OjB4OEK2OFM>
H146 M3rrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHNOlBKSzVyPUO1JI5O MX[yNFY5OjZ2Mx?=
H82 NFnhV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX[4OnIzUUN3ME2yOVAhdk1? NIfkNVczODZ6Mk[0Ny=>
DMS114 NEfSXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5OmxiUUN3ME22OFAhdk1? NH\Teo0zODZ6Mk[0Ny=>
HeLa NX3lRZd1TnWwY4Tpc44hSXO|YYm= NXy2NFQyOC5|LUGwJO69VQ>? NULyd3k2QCCq M2\veGROW09? M1j3PIlv[3KnYYPld{Bi[2W2eXzheIVlKEh|IFu5JEhJO0t7QXOpJIF1KDFyIN88US=> MYeyNFU{QDh2MB?=
HeLa Ml\3SpVv[3Srb36gRZN{[Xl? M1jZUVAvOy1zMDFOwG0> M{HDeFghcA>? MYTEUXNQ MUHpcoNz\WG|ZYOgZ4F{eGG|ZTCzJIFv\CB5IHHjeIl3[XSrb36g[I9{\SCmZYDlcoRmdnSueR?= NVHMcWFmOjB3M{i4OFA>
HeLa MmXuSpVv[3Srb36gRZN{[Xl? M2\2[VExKM7:TdMg NGe2NXg3NzF{L{K0JIg> MYDEUXNQ NYnjOXg{cW6mdXPld{BucXSxdHnjJIFk[3WvdXzheIlwdiCjbnSg[IVt[XmnZDDwNlEh\XiycnXzd4lwdg>? MmnjNlA2Ozh6NEC=
HeLa  NWTZeFR2TnWwY4Tpc44hSXO|YYm= MYqxNEDPxE4EoB?= NHi4bpU4KGh? MnzNSG1UVw>? MnjY[Il{enWydIOgco9zdWGuIIPwbY5ldGViY3jlZ4txd2mwdDDmeY5kfGmxbh?= NWrWVXo4OjB3M{i4OFA>
PBMC  NHnYTG1CeG:ydH;zbZMhSXO|YYm= MYOwMlUwOi9|IN88US=> M1\VUVI1NzR6IHi= NXTKWVk4cW6mdXPld{BieG:ydH;zbZMh\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MVmyNFQxPjl2Nx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Ac-H3 / Ac-H4 / Ac-tubulin ; 

PubMed: 29186204     


Mocetinostat increased acetylated histone 3 and 4 in a time- and dose-dependent manner in LMS cells. Mocetinostat did not increase acetylated tubulin expression.

Bad / Bid / Bak / Puma / Bax / Cleaved caspase-9 / Cleaved caspase-3 / Cleaved PARP; 

PubMed: 27551526     


(a and b) DU-145 cells were treated with various doses of mocetinostat for 24 h. Western blotting was performed using the indicated antibodies. 

29186204 27551526
Immunofluorescence
Nanog / MHC ; 

PubMed: 26240433     


c-Kit+ cells were treated with 2 µM MOCE for 2 or 7 days, as indicated. The cells were double-labeled with anti-Nanog (green) and anti-αMHC (red) antibodies. Nuclei were stained with DAPI (blue). The upper right section of each panel shows the enlargement of the box-selected area. Scale bars = 20 µm.

E-cadherin / ZEB1 ; 

PubMed: 25872941     


Immunoblot and immunofluorescence showing that mocetinostat treatment (1 μM, 48 h) reduced ZEB1 expression and induced E-cadherin in Panc1. Expression of histone deacetylases was not altered by mocetinostat, but histone acetylation was induced. Scale bar 10 μm.

26240433 25872941
Growth inhibition assay
Cell viability; 

PubMed: 26378038     


B. Cells were treated with increasing concentrations of mocetinostat for 48 hours and assayed by the WST-1 cell viability assay. C. IC50 values were calculated by the GraphPad Prism software. 

26378038
In vivo MGCD0103 significantly inhibites growth of human tumor xenografts in nude mice and the antitumor activity correlated with induction of histone acetylation in tumors. P.O. administration of MGCD0103 (2HBr salt) significantly decreases growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. MGCD0103 (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blockes growth of tumors compared with vehicle treatment alone with no change in body weight. In addition, MGCD0103 does not reduce WBC counts and is well tolerated. MGCD0103 is also orally active in many other human tumor xenograft models including NSCLC H1437. MGCD0103 at 80 mg/kg (free base) almost completely blocks the growth of H1437 tumors after 13 days of daily p.o. administration with no reduction of body weight in animals. [1] MGCD0103 reduces pulmonary arterial pressure more dramatically than tadalafil, a standard-of-care therapy for human pulmonary hypertension that functions as a vasodilator. Moreover, MGCD0103 improves pulmonary artery acceleration time and reduced systolic notching of the pulmonary artery flow envelope, which suggests a positive impact of the HDAC inhibitor on pulmonary vascular remodeling and stiffening. [2]

Protocol

Kinase Assay:[1]
- Collapse

HDAC enzyme assay in vitro:

The deacetylase enzyme assay is based on a homogeneous fluorescence release assay. Purified recombinant HDAC enzymes are incubated with MGCD0103 diluted in various concentrations for 10 minutes in assay buffer [25 mM HEPES (pH 8.0), 137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl] at room temperature. The substrate Boc-Lys(ε-Ac)-AMC is added to the reaction for further incubation at 37 °C. The concentration of the substrate and the incubation time varies for different isotypes of HDAC enzymes. A 20-min trypsin incubation at room temperature allows the release of the fluorophore from the deacetylated substrate. The fluorescent signal is detected by fluorometer at excitation of 360 nm, emission of 470 nm, and cutoff at 435 nm.
Cell Research:[1]
- Collapse
  • Cell lines: Human mammary epithelial cells (HMEC), human foreskin fibroblasts (MRHF) cells
  • Concentrations: 0-60 μM
  • Incubation Time: 72 hours
  • Method: Human mammary epithelial cells (HMEC) and human foreskin fibroblasts (MRHF) cells in 96-well plates are incubated with MGCD0103 at various concentrations for 72 hours at 37 °C in 5% CO2. MTT is added at a final concentration of 0.5 mg/ml and incubated with the cells for 4 hours before an equal volume of solubilization buffer [50% N,N-dimethylformamide, 20% SDS (pH 4.7)] is added. After overnight incubation, solubilized dye is quantified by reading at 570 nm using a reference at 630 nm. Absorbance values are converted to cell numbers according to a standard growth curve of the relevant cell line. The concentration which reduces cell numbers to 50% relative to DMSO-treated cells is determined as MTT IC5
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Female CD-1 nude mice bearing H1437 tumors
  • Dosages: 80 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 13 mg/mL (32.79 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 396.44
Formula

C23H20N6O

CAS No. 726169-73-9
Storage powder
in solvent
Synonyms MG0103
Smiles C1=CC=C(C(=C1)N)NC(=O)C2=CC=C(C=C2)CNC3=NC=CC(=N3)C4=CN=CC=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04299113 Recruiting Drug: Vinorelbine|Drug: Mocetinostat Rhabdomyosarcoma Jonsson Comprehensive Cancer Center|Mirati Therapeutics Inc.|Phase One Foundation May 14 2020 Phase 1
NCT02993991 Withdrawn Drug: Mocetinostat|Biological: Durvalumab Squamous Cell Carcinoma Head And Neck|Squamous Cell Carcinoma Mouth|Resectable Squamous Cell Carcinoma of Oral Cavity University Health Network Toronto|Mirati Therapeutics Inc.|AstraZeneca October 10 2017 Phase 1
NCT02805660 Completed Drug: mocetinostat|Drug: durvalumab Advanced Cancer Mirati Therapeutics Inc. May 2016 Phase 1|Phase 2
NCT02236195 Completed Drug: Mocetinostat Urothelial Carcinoma Mirati Therapeutics Inc. October 2014 Phase 2
NCT00666497 Terminated Drug: Azacitidine|Drug: MGCD0103 Acute Myeloid Leukemia (AML)|Myelodysplastic Syndrome (MDS) Mirati Therapeutics Inc. June 2008 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) supplier | purchase Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) cost | Mocetinostat (MGCD0103) manufacturer | order Mocetinostat (MGCD0103) | Mocetinostat (MGCD0103) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID